HOXB13 and ependymal tumor: In the present study, we confirm these findings in an independent institutional cohort of 143 patients with spinal cord tumors, including 111 ependymal tumors, and provide further evidence that strong nuclear HOXB13 immunostaining can distinguish MPE confirmed by DNA methylation profiling from the other types of spinal ependymal tumors with high sensitivity and specificity.